Thermo Fisher Scientific Inc. has announced the grand opening of its East Coast flagship Advanced Therapies Collaboration Center (ATxCC) in Philadelphia, marking the company’s second ATxCC in the United States following the opening of its Carlsbad, California, site.
Together, these centers expand the company’s nationwide network supporting cell and gene therapy (CGT) innovation, providing critical resources to biotech, biopharma and translational researchers developing next-generation cell-based immunotherapies.
Located within BioLabs for Advanced Therapeutics Philadelphia, a newly expanded 53,000-square-foot biotech incubator in the heart of the city, the Philadelphia ATxCC provides emerging startups and biopharma organizations with direct access to Thermo Fisher’s expert scientists, advanced process development technologies and collaboration opportunities.
"By embedding the ATxCC within the BioLabs community, we are creating a uniquely rich and accessible resource for founders and startup teams working on groundbreaking therapies in Philadelphia,” said Johannes Fruehauf, PhD, MD, Founder and CEO of BioLabs, the premier global network of life science incubators. “It will offer game-changing access to high-end technologies not only for our BioLabs members but also to external high-potential biotechs from across the East Coast and internationally.”
